Vanguard Capital Management LLC has filed an update regarding its beneficial ownership in Collegium Pharmaceutical, Inc., revealing a significant stake in the company. This filing is particularly important as it reflects Vanguard's ongoing investment strategy and interest in the pharmaceutical sector.

As of October 30, 2026, Vanguard Capital Management reported owning 1,627,026 shares of Collegium Pharmaceutical, representing approximately 4.97% of the company's common stock. The firm holds sole voting power over 245,798 shares, while it has sole dispositive power over the entire amount of shares reported. This update may impact Collegium's market dynamics and investor relations.

Background

Vanguard Capital Management LLC is based in Malvern, Pennsylvania, and is recognized for its investment management services. The firm is categorized under the SEC filings as an investment advisor. Collegium Pharmaceutical, Inc., the subject of this filing, is classified under the SIC code for pharmaceutical preparations. It operates primarily in Stoughton, Massachusetts.

What the Filing Says

The Schedule 13G/A filing indicates that Vanguard Capital Management has beneficially owned 1,627,026 shares of Collegium Pharmaceutical, Inc. The filing states, "This Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC..." This update shows the firm's commitment to its investment in Collegium.

Impact

This update may affect various stakeholders, including Collegium's management, existing shareholders, and potential investors. Vanguard's significant ownership stake may influence Collegium's strategic decisions and market perception.

What's Next

The filing does not say what happens next.